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Background: Soluble CD40 ligand (sCD40L) and matrix metalloproteinase 9 (MMP-9) are inflammation markers and
have been poorly described in infectious disease. In this prospective study, we describe the sera kinetics of these
two molecules in the course of treatment follow up in human visceral leishmaniasis (VL).
Methods: Sera from VL patients were collected before and during follow up of regular Antimony treatment.
sCD40L and MMP-9 were measured by Luminex assay. Paired analysis by Wilcoxon signed test was used for
comparison of values of the same subjects before and after initiation of treatment. Correlations between clinical
data and parasite load with the serum levels of sCD40L and MMP-9 were performed by Spearman test. Tests were
considered statistically significant if the probability of a type I error was less than 5% (p-value < 0.05).
Results: While sCD40L and MMP-9 were not observed in sera from non endemic controls which are at low risk of
Leishmania chagasi infection, elevated levels were observed in sera from VL patients, and an increase in sCD40L and
MMP-9 levels were detectable during the follow-up of VL patients undergoing antimony treatment. sCD40L levels
were also high in individuals living in endemic settings at high risk of infection (endemic controls). Additionally,
negative correlations were found between spleen sizes and MMP-9 before treatment and sCD40L at day 15 of
treatment. Negative correlations were also found between parasite load with both sCD40L and MMP-9.
Conclusion: Serum sCD40L and MMP-9 are identified as new and simple biomarkers in two situations: (i)
monitoring the success of therapy and (ii) predicting favorable clinical outcome of human VL.
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Visceral leishmaniasis (VL) is a disease caused by systemic
infection with protozoa of the genus Leishmania, trans-
mitted to mammalian hosts by phlebotomine sandflies.
Human VL is characterized by fever, hepatosplenomegaly,
anemia, leukopenia, and severe weight loss and is fatal* Correspondence: jesus-amelia@uol.com.br
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distribution, and reproduction in any mediumif not treated. VL is associated with a marked impairment
of leishmania-specific Th1 response, as evaluated by
in vitro leishmania antigen stimulation of peripheral blood
mononuclear cells (PBMC) [1]. However, high levels of
proinflammatory cytokines, including IFN-γ, have been
detected in serum and bone marrow of VL patients [2-4].
IL-12 and IFN-γ have been associated with a protective
immunity in individuals living in an endemic area [5].
These cytokines activate macrophages to release several
microbicidal agents to kill the parasites [6]. High amounts
of IL-10 are also detected in sera and bone marrow of VL
patients, and this cytokine is well known to have antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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response in VL patients [7-9] and directly correlates to
parasite load [10]. The production of IL-10, IL-12 and
IFN-γ is dependent on cellular associated costimulatory
molecules such as CD40 and CD40L [11].
CD40 was identified on B cells, monocytes, dendritic
cells, endothelial and epithelial cells [12]. Cellular CD40L,
a member of the TNF family, is primarily expressed on
activated CD4+ T cells and on a small proportion of
CD8+ T cells and platelets [12]. The interaction of CD40
and CD40L is important for activating antigen presenting
cells, T cells and macrophages [12]. CD40-CD40L signaling
has an important role during various parasite infections
(reviewed in [13]). While strong CD40-CD40L signaling
induces IL-12 and IFN-γ production and drives T cells
to a Th1 phenotype, weak signaling induces IL-10 and
TGF-β, allowing T cells to differentiate to a Th2 or T
regulatory phenotype (reviewed in [14]). In the context
of leishmaniasis, it is known that L. major amastigotes
deviate the cellular CD40 signaling pathway by inducing
ERK 1/2 and IL-10 production, which inhibits the
p38MAPK/IL-12 pathway [15].
CD40-CD40L signaling is also important for antibody
isotype switching, and germinal center formation, and
patients with congenital X-linked hyper IgM syndrome
(X-HIM), caused by the lack of functional CD40L, present
an increased incidence of infections with opportunistic
pathogens (reviewed in [13]). Peripheral blood mononuclear
cells (PBMC) from X-HIM patients also secrete markedly
lower amounts of IFN-γ and IL-12 in response to T. gondii
[16]. CD40L knockout (-/-) mice are more susceptible
to L. major infection [17], while mice treated with
molecules that bind CD40, thereby mimicking the ef-
fects of soluble CD40L, exhibit a decreased severity
of experimental L. major or T. cruzi infection [17,18].
The CD40-CD40L signaling pathway also is involved in
matrix metalloproteinases (MMPs) expression, including
MMP-9 [19,20].
CD40L may be expressed as an heteromultimeric com-
plex [21]. After cleavage of the transmembrane protein by
naturally occurring MMPs, the soluble form present in
the plasma (sCD40L) still binds to CD40 and delivers
biological signals [22]. This molecule binds cell surface
CD40 and induces a strong activation of antigen presenting
cells (APC) independent of T cell help, resulting in IL-12
and IFN-γ production [23].
MMPs are produced by different cell types, including
macrophages, lymphocytes, endothelial cells, and are
associated with remodeling and modulation of inflam-
mation [24]. In tuberculosis, MMP-9 is required for
macrophages recruitment and tissue remodeling for
the formation of tight well-organized granulomas [25].
MMP-9 also contributes to the myocarditis induced by T.
cruzi, by favoring the infiltration of immune cells [26].sCD40L and MMP-9 have been described in cardiovascu-
lar disease as mediators of inflammation in arterial coron-
ary disease, and are considered markers of poor prognosis
[27,28]. In infectious diseases, increased sCD40L levels
are detected in the serum of HIV-1 and Sepsis, and are
associated with poor prognosis [29,30]. In leishmaniasis,
MMP-9, along with other leishmanicidal products are
released by infected macrophages in vitro [31]. Further-
more, in canine visceral leishmaniasis high levels of serum
MMP-9 is associated with multi-systemic inflammatory
lesions [32]. However, the role of MMP-9 and sCD40L
has not been explored in human visceral leishmaniasis. In
this novel study, we describe the serum levels of sCD40L
and MMP-9 in VL patients in different stages of disease
and in post treatment clinical evolution. We also compare
their levels with individuals without disease but living in
endemic areas and at the same household of the VL cases.
Methods
Study design and ethics issues
This was a prospective study performed in Hospital
Universitário – Universidade Federal de Sergipe – Brazil,
approved by the Ethics Committee of University Hospital
from Universidade Federal de Sergipe. All individuals, or
their legal guardians, signed an informed consent form.
Pregnant women, patients receiving immunosuppressive
treatments and patients with comorbidities (including HIV
infection and malignancy) were excluded.
Study population and follow-up
Initially, 45 patients (mean ± SD 15 ± 15 years; 25 males
and 20 females) with confirmed VL were selected for this
study. The diagnostic criteria used for inclusion were
identification of Leishmania on bone marrow aspirates by
direct exam and culture in NNN media (Sigma-Aldrich,
St Louis, MO), and rK39 serological test (Kalazar Detect®
Rapid Test; InBios International Inc., Seattle, WA). Patients
were examined using a standard protocol containing the
following information: identification, clinical complaints,
physical exam, and the results of laboratory tests performed
(distinct from data used in this study). After diagnosis,
patients received regular Antimony treatment (20 mg
Sbv/Kg for 20 days). Liver and spleen sizes were evaluated
by two observers by palpation and reported as the distance
to the rib border in cm at diagnosis and every five day
during the treatment until the end of therapy, and later,
every 3 months until one year post treatment.
Several groups were included to serve as controls. A
group of individuals (either household contacts or relatives)
living in the same area as the patients but with no signs of
clinical disease were recruited (endemic controls) (n = 37).
Healthy subjects, United States Citzens, thus not exposed
to the infection (non endemic controls) (n = 24) were also
included. Sera of chronic Chagas disease patients (n = 29)
Table 1 Demographic and clinical characteristics of VL
patients
Variables (pre-treatment) VL patients (n = 45)
Age (mean ± SD) 15 ± 15 years
Males n (%) 25 (55.5%)
Spleen size (mean ± SD) 9.1 ± 4.08
White blood cell count 3035 ± 1351
Neutrophils 1041 ± 745.2
Platelets 181, 21 ± 63,844
Hb 8.475 ± 1.264
Confirmatory of VL
r K39 (n = 45) 100%
L eishmania culture (n = 17) 100%
Parasite load (n = 15) 100%
AST (mean ± SD) 119.6 ± 188.4U/ml
ALT (mean ± SD) 79.20 ± 103.4U/ml
Hb hemoglobine.
VL Visceral leishmaniasis.
rK39 serological test specific for Kalazar.
AST Aspartate aminotransferase.
ALT Alanine aminotransferase.
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public health diseases. Clinical data were not available
regarding serum from patients with Chagas disease.
Laboratorial data
Blood samples without anticoagulant were collected for all
study participants, for VL patients, blood was collected
before specific leishmania therapy, day 0 (D0) (n = 45)
and at several times after the initiation of treatment
(D15, n = 42; D30, n = 35; D45, n = 36; D60, n = 30; and
D180, n = 11). Sera were collected and stored at -70°C
until sCD40L, and MMP-9 concentrations were determined
by a Luminex assay, performed according to the manufac-
turer’s instructions (Millipore, Massachusetts, USA). The
levels of sCD40L were measured in all sera samples col-
lected from VL patients, while MMP-9 concentrations
were determined in D0, n = 37; D15, n = 30; D30, n = 36;
D45, n = 29; D60, n = 29; and D180, n = 6. The measure-
ment of transaminases (ALT and AST) by a chemistry
system (Vitros® 5.1 FS - Ortho-Clinical Diagnostics -
Johnson & Johnson, New York, USA) was adopted as a
hepatic damage marker before treatment in VL patients
and was also tested in endemic controls (n = 30; n = 29,
respectively). The few missing values for laboratorial data
were due to samples limitations.
Parasite load
Evaluation of parasite load was carried out in blood sam-
ples of VL patients before treatment D0 (n = 15), at D30
(n = 13) and D60 (n = 13) of treatment. The blood samples
were collected in tubes containing Paxgene (PreAnalytiX
GmbH, Hombrechtikon), according to manufacture’s
instructions. Nucleic acid extraction was performed by
using a QIAamp DNA, Blood Mini Kit (Qiagen, Valencia,
CA). The Real-time PCR based on TaqMan Probe was
applied for accurate quantification of Leishmania in blood
samples of VL patients, described previously[33]. Specific
primers based on conserved region of Leishmania 18S ribo-
somal DNA gene were disigned by using ABI FileBuilder
3.1 and consisted of; forward 5′- CCGTTTCGGCTTTT
GTTGGTTTTAA; GCGATGGGAAAGCACTTGTC-3′;
and reporter: CAGCTCCATAATCTCC (Applied Biosystems
Inc., Foster City, CA). Standards and a no template
control were included in each run. Patient samples were
first examined in duplicate, then, samples that did not
amplify, or had very late amplification, were re-examined
in triplicate.
Statistical analysis
Kolmogorov-Smirnov normality test was applied. Data
were analyzed for different groups (non-paired analysis)
by a nonparametric Kruskall-Wallis with post Dunn’s
multiple comparison test. Student T test for parametric
or Mann–Whitney for the non-parametric samples wasused for two groups comparisons. Paired analysis by
Wilcoxon signed test was used for comparison of values
of the same subjects before and after initiation of treatment.
Correlations between clinical data and parasite load with
the serum levels of sCD40L and MMP-9 were performed
by Spearman test. All tests were carried out using Graph
Pad Prism, version 4.0, 2005. Tests were considered statis-
tically significant if the probability of a type I error was
less than 5% (p-value < 0.05).
Results
Demographical and clinical data of VL patients
Demographic and clinical data of VL patients before
treatment are presented in Table 1. The mean ± SD of age
was 15 ± 15 years. Fifty five percent of patients were males.
The mean ± SD of spleen size was 9.1 ± 4.08 under the left
costal rib. All patients had diagnosis of VL confirmed by
rK39 serology, 17 of the patients had bone marrow culture
for leishmania performed and were confirmed as positive,
and parasite load was assessed in 15.
Higher levels of sCD40L and MMP-9 in VL patients
Given that VL and Chagas disease are inflammatory
diseases that commonly present with organomegaly, it
was not surprising that all patients had detectable
levels of circulating sCD40L (Figure 1A). In contrast,
among 24 non endemic controls, only 5 presented with
detectable serum levels of sCD40L (Figure 1A). It was
observed that both Chagas disease and VL patients
presented high serum levels of sCD40L (mean ± SD;
3,935 ± 2,804 pg/ml and 3,579 ± 3,878 pg/ml, respectively)
Figure 1 Serum levels of sCD40L and MMP-9 in VL patients, Chagas disease patients and non endemic controls. (A) Compares sCD40L
levels in non endemic controls, VL patients and Chagas disease patients as measured by Luminex assay (p <0.001). (B) Compares MMP-9 in non
endemic controls and VL patients (p < 0.05), and Chagas disease patients (p < 0.0001) *Mann Whitney test.
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21,815 ± 20,164 pg/ml, respectively); levels significantly
higher than those of the non endemic controls (mean ± SD
of sCD40L was 8.8 ± 20.26 pg/ml; and of MMP-9 was
13,393 ± 5,363 pg/ml) (p < 0.05) (Figure 1). Thus, both
sCD40L and MMP-9 levels were evaluated in sera of
Chagas disease and VL patients compared with those
found in non endemic controls.
Protective role of sCD40L and MMP-9
Endemic control subjects had serum sCD40L (mean ± SD;
16,602 ± 19,066 pg/ml) and MMP-9 (mean ± SD; 155,426 ±
72,757 pg/ml) levels higher than non endemic controls
(p < 0.001). Interestingly, levels of these analytes in en-
demic controls were also higher than those in VL patients
(p < 0.005) (Figure 2). These data suggest a protective role
of these molecules. This hypothesis is supported by the
observation that, when sCD40L and MMP-9 levels were
analyzed throughout VL treatment, a significant increase
was detected throughout treatment (p < 0.005) (Figure 2).
At 15, 30, 45, 60 and 180 days after treatment initiation,
the levels of sCD40L in VL patients were similar to
those of the endemic control subjects (Figure 2A). MMP-9
levels also increased progressively from day 15 to 180 after
treatment initiation, but still remained lower than the
endemic controls (p < 0.05) (Figure 2B).
To further evaluate a potential protective role of
sCD40L and MMP-9, we compared the sera levels of these
molecules in VL patients with spleen and liver sizes.
No significant correlation was found between serum
levels of sCD40L and MMP-9 and liver size (data not
shown). In order to evaluate if MMP-9 is involved in
hepatocyte damage, the sera levels of transaminases
(ALT and AST) were correlated with the sera levels of
sCD40 and MMP-9 from VL patients before treatment
and from endemic controls. Although VL patients
showed levels of ALT (79.20 ± 103.4 U/ml) and AST
(119.6 ± 188.4 U/ml), higher than those of the endemiccontrols (24.93 ± 11.45 U/ml; 23.38 ± 6.99 U/ml, ALT and
AST, respectively) (Figure 3). No significant correlations
were observed between the levels of these enzymes and
the sCD40L or MMP-9 levels. In fact, despite having
higher levels of MMP-9 in their sera, the endemic controls
did not present altered transaminases.
A negative correlation between spleen size and serum
levels of MMP-9 was observed before treatment (n = 30;
r = −0.38; p < 0.05). Similarly, sCD40L levels and spleen
size correlated at D15 of treatment (n = 33; r = −0.36;
p < 0.05) (Figure 4A and B). Negative correlations between
parasite load and levels of MMP-9 (n = 39; r = −0.50;
p < 0.001) and sCD40L (n = 41; r = −0.34; p < 0.05) were
also observed (Figure 4C and D).
Discussion
sCD40L and MMP-9 are inflammation markers extensively
studied in cardiac disease [27,34,35] but there is no previ-
ous data regarding the soluble CD40L (sCD40L) during
parasitic infections in humans. In this novel study, we
described the presence of these two molecules circulating
during parasitic infections. Our results demonstrate that
sCD40L and MMP-9 are increased in both Chagas disease
and VL. The increasing levels in VL patients during
treatment follow-up strongly suggest that theses mole-
cules are markers of favorable clinical evolution. Although
leishmania-specific delayed-type hypersensitivity skin
reactions (DTH) was not performed in endemic control
subjects in the present study, asymptomatic infection
(DTH positive) is present in 40% of subjects in endemic
areas in Brazil and is frequently associated with the
presence of a classical VL case in the family or neigh-
borhood [36,37]. In addition, non endemic controls
present lower serum levels of sCD40L and MMP-9.
Taken together, these data reinforce our hypothesis that
high levels of these molecules in endemic controls may
have a protective role in clinical evolution from leishmania
infection to VL.
Figure 2 Serum levels of sCD40L and MMP-9 in follow up of VL treatment and of endemic control subjects. (A) Compares sera levels of
sCD40L and (B) MMP-9 in VL patients before (D0) and during treatment follow-up (D15, D30, D45, D60, D180) as measured by Luminex assay.
*Mann–Whitney test and ** Wilcoxon signed rank test.
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of the CD40-CD40L signaling pathway for protection
against a variety of parasites (reviewed in [13]). CD40
stimulation induces anti-microbial activity against T.
cruzi, mediated by the production of nitric oxide (NO)
and of free radicals, which require IL-12 and IFN-γ pro-
duction. Mice infected with T. cruzi and treated with
CD40L exhibit a decrease in parasitemia and in mortality
that are accompanied by prevention of the immunosup-
pression that typically follows T. cruzi infection [18].
In leishmania infection, the role of CD40L is clearly
demonstrated. Knockout mice have an increased suscepti-
bility to L. donovani infection [38]. CD40-CD40L signaling
not only regulates immunity but also influences the out-
come and response to pentavalent antimony (Sb) treatment,
the conventional chemotherapy for VL [38]. CD40L is
necessary to generation of IL-12 and INF-γ [11]. It is
assumed that IL-12 drives the Th1 cell-associated
mechanism and induces IFN-γ, both cytokines guide T
cells and blood monocytes into granulomas at parasitizedtissue focus and IFN- γ stimulates effector monocytes and
macrophages to kill intracellular parasites (reviewed in
[39]). Response to Sb therapy requires an intact type
Th1 (INF-γ and IL-12 secretion) which depends on
CD40-CD40L interaction [11,38]. Moreover, CD40-CD40L
simultaneously with TNF-α is a potent inducer of nitric
oxide production, which plays a main role in antimicrobial
activity[40]. Previous studies suggest that sCD40L is a
marker of disease and poor prognosis of various infec-
tions, [29,30,41,42]. In sepsis patients, sCD40L higher than
3.5 ng/ml present a worse survival curve, as compared to
the patients with lower than this value (Odds ratio of 2.35
for mortality)[29]. Increased sCD40L levels are detected in
the serum of HIV infected subjects and cerebrospinal fluid
of patients with AIDS dementia [30,41], and is described
to inhibit plasmocytoid dendritic cell-derived IFN-α
production [43]. The levels of sCD40L also are higher in
untreated than in anti-retrovirus treated HIV patients
[44]. Our data in VL patients is the first suggesting a
protective role of sCD40L. It is possible that in parasitic
Figure 3 Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in VL patients and endemic controls.
(A) Compares the levels of AST (p < 0.05) and (B) ALT (p < 0.01) between VL patients and the endemic controls. * Mann Whitney test. RV;
reference value.
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ive immune response, the presence of sCD40L is important
to restore this response. In fact, a previous study indicates
that L. major amastigotes modulate the signaling path-
way downstream of membrane CD40 engagement by
inducing ERK 1/2 and IL-10 production, which inhibits
the p38MAPK/IL12 pathway [27]. As sCD40L has been
described to provide a strong signal to APC [23], it might
be effective at restoring the IL-12 production and thereby
have a protective role in VL clinical outcome.
During the course of VL infection there is extensive
parasite multiplication that results in a high parasite
burden in the spleen and liver. The enlargement of theFigure 4 Correlation between sCD40L and MMP-9 levels with spleen
MMP-9 and spleen size before treatment (n = 30; r = −0.38; p < 0.05). (B) Co
(n = 33; r = −0.36; p < 0.05). (C) Correlation between sCD40L with parasite lo
parasite load at D0, D30, D60 (n = 39; r = −0.50; p < 0.001). Spearman correlspleen and liver is a cardinal feature of human VL and
the return of these organs to their normal impalpable state
has long been used to evaluate cure. The reductions of
spleen or liver after the initiation of treatment (data not
shown) are observed at D15 of treatment, and at this time
point, the reduction of spleen size correlates with serum
level of sCD40L.
Our data also indicate elevated sCD40L in Chagas disease
patients and it is possible that sCD40L levels may be
related to the control of parasitemia seen in the chronic
stage of disease. Since Trypanosoma cruzi infection also
produces an intense inflammatory response in diverse
tissues including the heart [45], the sCD40L could besize or parasite load during VL treatment. (A) Correlation between
rrelation between sCD40L and spleen size at D15 of treatment
ad at D0, D30, D60 (n = 41; r = −0.34; p < 0.05). (D) MMP-9 with
ation test.
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was available for these patients, however, further studies
are required to associate these data with clinical
outcome.
The CD40-CD40L signaling pathway also is involved in
matrix metalloproteinases (MMPs) expression, including
MMP-9 [19,20]. Our data also shows increased levels of
MMP-9, following the same profile of sCD40L. Thus, the
sCD40L, biologically active, may be contributing to increase
the sera levels of MMP-9, previously mentioned. High
levels of serum matrix metalloproteinases, MMP-2 and
MMP-9, were observed in dogs with natural VL, and the
authors suggest that these enzymes play a role in multi-
systemic inflammatory lesions found in VL [32]. However,
in our study we observed that, at D0 of treatment, patients
with the highest levels of MMP-9, in their sera, had
smaller spleens sizes than patients with lower MMP-9
levels. MMP-9 has an essential function in matrix com-
pounds degradation during the transmigration of host
defense cells and during macrophages migration [46,47].
On the other hand, MMP-9 along with others MMPs is
involved in regulation of the inflammatory response in
several circumstances, including the direct cleavage of
immune system proteins [42].
Alternatively, sCD40L is exposed to cleavage by the
action of MMPs, liberating soluble CD40L [22]. Thus,
in VL, the high levels of MMP-9 can play a role in the
cleavage of sCD40L from the cell membrane, promoting
the increase of CD40L in its soluble form. In carcinoma
cells, sCD40L induced cytotoxicity and is enhanced by
inhibition of metalloproteinase cleavage [48]. In this
context, it is difficult to know which of the molecule initi-
ate these events, but they are both involved in a regulatory
network and associated with a clear protective response.
Confirming their role as a marker of favorable clinical
evolution in VL patients, inverse correlations between
the serum sCD40L levels and MMP-9 with parasite load
were found. Serum levels of IL-10 are also a good marker
of disease severity and directly correlated with parasite
load, considering its immunosuppressive role of macro-
phage microbicidal mechanisms. Although further studies
are required to understand both the mechanisms by which
the sCD40L and MMP-9 influence disease outcome in
human VL, and the timing of the release of these molecules
in sera after the infection, sCD40L and MMP-9 represent
useful biomarkers with which to predict favorable response
to VL therapy. In addition, as there is no marker of pro-
tection of clinical evolution from leishmania infection to
clinical disease, and in some endemic areas it is difficult to
assess clinical data of households contacts, sCD40L and
MMP-9 represent important predictive clinical outcome
biomarkers.
MMP-9 in macrophage-hepatocyte co-culture superna-
tants is associated with liver damage, and the release oftransaminases AST and ALT [31]. Leishmania infection
activates macrophages resulting in the release of several
leishmanicidal agents, including MMPs, which in excess,
can cause severe tissue/organ damage (reviewed in [49]).
In fact, VL patients present evidences of liver damage,
demonstrated by increase in AST and ALT. However, no
correlations are observed between the MMP-9 and
transaminases levels in VL patients. To further support
that MMP-9 is not involved in hepatocyte damage,
endemic controls present high levels of MMP-9 and no
markers of hepatic damage are detected in these subjects
(normal levels of AST and ALT). Although, MMP-9 is
considered a hallmark of inflammation [42], our data
suggest that it is not involved in tissue damage.
Conclusion
This study identifies serum sCD40L and MMP-9 as new
and simple biomarkers in two situations: (i) monitoring
the success of therapy and (ii) predicting favorable clinical
outcome of human VL.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FAO helped to collect the data, built the database, performed the statistical
analysis and wrote the paper. CVOS, NPD and ROP conduct the treatment
follow up of the VL patients, and collected medical data and the serum
samples. MSD, JAG and AB performed the immunoassays and helped to
draft the manuscript. TRM helped to collect patients samples and draft the
manuscript. SGR participated in study design and financed the
immunological tests. RPA participated in study design, supervision of clinical
study, and conduct the treatment and follow up of the VL patients. ARJ
participated in the supervision of clinical study, provide major help to the
first author to perform the statistical analysis and in the manuscript
preparation. All authors read and approved the final version of the
manuscript.
Acknowledgements
We thank to the Pediatric and Infectious Disease Clinic Group from the
University Hospital, Universidade Federal de Sergipe. This work was
supported by: Fundação de Apoio à Pesquisa e à Inovação Tecnológica do
Estado de Sergipe (FAPITEC)/ Brazilian Research National Council (CNPq)/
Ministério da Saúde (Programa de Apoio a Projetos para o Sistema Único de
Saúde – PPSUS Edital 08/2009 and Programas de Núcleos de Excelência –
PRONEX, Processo nº 019.203.02712/2009-8); Bill & Melinda Gates Foundation
[grant number 42387], Seattle, USA. Programa Nacional de Incentivo à
Pesquisa em Parasitologia Básica, Edital Nº 032/2010, Coordenação de
Aperfeiçoamento de Pessoal de Nível Superior (CAPES). ARJ and RPA are
scientists from the Brazilian Research National Council (CNPq).
Author details
1Molecular Biology Laboratory, Hospital Universitário – Universidade Federal
de Sergipe, Rua Claudio Batista s/n, Bairro Sanatório, Aracaju, Sergipe
49060-10, Brazil. 2IDRI- Infectious Disease Research Institute, Seattle, WA
98102, USA. 3Instituto de Investigação em Imunologia (iii) – Institutos
Nacionais de Ciência e Tecnologia (INCT), CNPq, São Paulo, Brazil.
Received: 17 August 2012 Accepted: 10 July 2013
Published: 19 July 2013
References
1. Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD Jr: Absence of
gamma interferon and interleukin 2 production during active visceral
leishmaniasis. J Clin Invest 1985, 76:2066–2069.
de Oliveira et al. BMC Infectious Diseases 2013, 13:331 Page 8 of 9
http://www.biomedcentral.com/1471-2334/13/3312. Rai AK, Thakur CP, Singh A, Seth T, Srivastava SK, Singh P, Mitra DK:
Regulatory T cells suppress T cell activation at the pathologic site of
human visceral leishmaniasis. PLoS One 2012, 7:e31551.
3. Goto H, Prianti M: Immunoactivation and immunopathogeny during
active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 2009, 51:241–246.
4. Barral-Netto M, Diez R, Badaro R, Sampaio D, Barral A, Carvalho EM, Falcoff E:
Serum interferon activity of patients with leishmaniasis. Braz J Med Biol
Res 1989, 22:1485–1487.
5. Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H,
Johnson WD Jr: Immunologic markers of clinical evolution in children
recently infected with Leishmania donovani chagasi. J Infect Dis 1992,
165:535–540.
6. Carvalho EM, Bacellar OA, Reed S, Barral A, Rocha H: Visceral leishmaniasis:
a disease associated with inability of lymphocytes to activate
macrophages to kill leishmania. Braz J Med Biol Res 1988, 21:85–92.
7. Bacellar O, D'Oliveira A, Jeronimo S Jr, Carvalho EM: IL-10 and IL-12 are the
main regulatory cytokines in visceral leishmaniasis. Cytokine 2000,
12:1228–1231.
8. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa A, Vasconcelos AW,
Pearson RD, Abrams JS, Locksley RM: Potential role for interleukin-10 in
the immunosuppression associated with kala azar. J Clin Invest 1993,
92:2626–2632.
9. Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel
FP: Determinants of response to interleukin-10 receptor blockade
immunotherapy in experimental visceral leishmaniasis. J Infect Dis 2003,
188:458–464.
10. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, Salotra P:
Quantification of parasite load in clinical samples of leishmaniasis
patients: IL-10 level correlates with parasite load in visceral
leishmaniasis. PLoS One 2010, 5:e10107.
11. McDyer JF, Goletz TJ, Thomas E, June CH, Seder RA: CD40 ligand/CD40
stimulation regulates the production of IFN-gamma from human
peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent
manner. J Immunol 1998, 160:1701–1707.
12. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2–17.
13. Subauste CS: CD40 and the immune response to parasitic infections.
Semin Immunol 2009, 21:273–282.
14. Mathur RK, Awasthi A, Saha B: The conundrum of CD40 function: host
protection or disease promotion? Trends Parasitol 2006, 22:117–122.
15. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B: Reciprocal
CD40 signals through p38MAPK and ERK-1/2 induce counteracting
immune responses. Nat Med 2004, 10:540–544.
16. Subauste CS, Wessendarp M, Sorensen RU, Leiva LE: CD40-CD40 ligand
interaction is central to cell-mediated immunity against Toxoplasma
gondii: patients with hyper IgM syndrome have a defective type 1
immune response that can be restored by soluble CD40 ligand trimer.
J Immunol 1999, 162:6690–6700.
17. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski
CR: CD40 ligand is required for protective cell-mediated immunity to
Leishmania major. Immun 1996, 3:283–289.
18. Habib M, Noval Rivas M, Chamekh M, Wieckowski S, Sun X, Bianco A,
Trouche N, Chaloin O, Dumortier H, Goldman M, Guichard G, Fournel S, Vray
B: Cutting edge: small molecule CD40 ligand mimetics promote control
of parasitemia and enhance T cells producing IFN-gamma during
experimental Trypanosoma cruzi infection. J Immunol 2007,
178:6700–6704.
19. Schonbeck U, Libby P: The CD40/CD154 receptor/ligand dyad. Cell Mol Life
Sci 2001, 58:4–43.
20. Malik N, Greenfield BW, Wahl AF, Kiener PA: Activation of human
monocytes through CD40 induces matrix metalloproteinases. J Immunol
1996, 156:3952–3960.
21. Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D: Heteromultimeric
complexes of CD40 ligand are present on the cell surface of human T
lymphocytes. J Biol Chem 1997, 272:911–915.
22. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA: A soluble
form of TRAP (CD40 ligand) is rapidly released after T cell activation.
Eur J Immunol 1995, 25:1749–1754.
23. Haanen JB, Schumacher TN: Vaccine leads to memory loss. Nat Med 2007,
13:248–250.
24. Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem 1999,
274:21491–21494.25. Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, Basaraba RJ, Orme IM,
Matrisian LM, Izzo AA: Role for matrix metalloproteinase 9 in granuloma
formation during pulmonary Mycobacterium tuberculosis infection.
Infect Immun 2006, 74:6135–6144.
26. Gutierrez FR, Lalu AA, Mariano FS, Milanezi CM, Cena J, Gerlach RF, Santos JE,
Torres-Duenas D, Cunha FQ, Schulz R, Silva JS: Increased activities of cardiac
matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9
are associated with mortality during the acute phase of experimental
Trypanosoma cruzi infection. J Infect Dis 2008, 197:1468–1476.
27. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher
AM, Simoons ML: Soluble CD40 ligand in acute coronary syndromes. N
Engl J Med 2003, 348:1104–1111.
28. Tousoulis D, Androulakis E, Papageorgiou N, Briasoulis A, Siasos G,
Antoniades C, Stefanadis C: From atherosclerosis to acute coronary
syndromes: the role of soluble CD40 ligand. Trends Cardiovasc Med 2010,
20:153–164.
29. Lorente L, Martin MM, Varo N, Borreguero-Leon JM, Sole-Violan J, Blanquer
J, Labarta L, Diaz C, Jimenez A, Pastor E, Belmonte F, Orbe J, Rodriguez JA,
Gomez-Melini E, Ferrer-Aguero JM, Ferreres J, Lliminana MC, Paramo JA:
Association between serum soluble CD40 ligand levels and mortality in
patients with severe sepsis. Crit Care 2011, 15:R97.
30. Sipsas NV, Sfikakis PP, Kontos A, Kordossis T: Levels of soluble CD40 ligand
(CD154) in serum are increased in human immunodeficiency virus type
1-infected patients and correlate with CD4(+) T-cell counts. Clin Diagn
Lab Immunol 2002, 9:558–561.
31. Costa JD, de Melo AC N, Vermelho AB, Meirelles N, Porrozzi R: In vitro
evidence for metallopeptidase participation in hepatocyte damage
induced by Leishmania chagasi-infected macrophages. Acta Trop 2008,
106:175–183.
32. Melo GD, Marangoni NR, Marcondes M, Lima VM, Machado GF: High levels
of serum matrix metalloproteinases in dogs with natural visceral
leishmaniosis: a preliminary report. Vet J 2011, 188:243–245.
33. Schulz A, Mellenthin K, Schonian G, Fleischer B, Drosten C: Detection,
differentiation, and quantitation of pathogenic leishmania organisms by
a fluorescence resonance energy transfer-based real-time PCR assay.
J Clin Microbiol 2003, 41:1529–1535.
34. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L,
Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A,
Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M,
Collen D, Daemen MJ, Carmeliet P: Inhibition of plasminogen activators or
matrix metalloproteinases prevents cardiac rupture but impairs
therapeutic angiogenesis and causes cardiac failure. Nat Med 1999,
5:1135–1142.
35. Palombo D, Maione M, Cifiello BI, Udini M, Maggio D, Lupo M: Matrix
metalloproteinases. Their role in degenerative chronic diseases of
abdominal aorta. J Cardiovasc Surg (Torino) 1999, 40:257–260.
36. Lima ID, Queiroz JW, Lacerda HG, Queiroz PV, Pontes NN, Barbosa JD,
Martins DR, Weirather JL, Pearson RD, Wilson ME, Jeronimo SM: Leishmania
infantum chagasi in northeastern Brazil: asymptomatic infection at the
urban perimeter. AmJTrop Med Hyg 2012, 86:99–107.
37. Caldas AJ, Costa JM, Silva AA, Vinhas V, Barral A: Risk factors associated
with asymptomatic infection by Leishmania chagasi in north-east Brazil.
Trans R Soc Trop Med Hyg 2002, 96:21–28.
38. Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP:
Modulation of T-cell costimulation as immunotherapy or
immunochemotherapy in experimental visceral leishmaniasis. Infect
Immun 2003, 71:6453–6462.
39. Murray HW, Montelibano C, Peterson R, Sypek JP: Interleukin-12 regulates
the response to chemotherapy in experimental visceral Leishmaniasis.
J Infect Dis 2000, 182:1497–1502.
40. Portillo JAC, Feliciano LM, Okenka G, Heizel F, Subauste MC, Subauste C:
CD40 and tumour necrosis factor-a co-operate to up-regulate inducuble
nitric oxide synthase expression in macrophages. Immunobiol 2007,
135:135–150.
41. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S,
Maggirwar SB: Functional synergy between CD40 ligand and HIV-1 Tat
contributes to inflammation: implications in HIV type 1 dementia.
J Immunol 2007, 178:3226–3326.
42. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure
S, Proost P, Van Damme J: Gelatinase B functions as regulator and
effector in leukocyte biology. J Leukoc Biol 2001, 69:851–859.
de Oliveira et al. BMC Infectious Diseases 2013, 13:331 Page 9 of 9
http://www.biomedcentral.com/1471-2334/13/33143. Donhauser N, Pritschet K, Helm M, Harrer T, Schuster P, Ries M, Bischof G,
Vollmer J, Smola S, Schmidt B: Chronic immune activation in HIV-1
infection contributes to reduced interferon alpha production via
enhanced CD40:CD40 ligand interaction. PLoS One 2012, 7:e33925.
44. Olmo M, Saumoy M, Alonso-Villaverde C, Penaranda M, Gutierrez F, Romeu
J, Larrousse M, Curto J, Domingo P, Oteo J, Vila A, Podzamczer D: Impact of
antiretroviral therapy interruption on plasma biomarkers of
cardiovascular risk and lipids: 144-week final data from the STOPAR
study. HIV Med 2012, 13:488–498.
45. Teixeira MM, Gazzinelli RT, Silva JS: Chemokines, inflammation and
Trypanosoma cruzi infection. Trends Parasitol 2002, 18:262–265.
46. Gong Y, Hart E, Shchurin A, Hoover-Plow J: Inflammatory macrophage
migration requires MMP-9 activation by plasminogen in mice.
J Clin Invest 2008, 118:3012–3024.
47. Reichel CA, Rehberg M, Bihari P, Moser CM, Linder S, Khandoga A,
Krombach F: Gelatinases mediate neutrophil recruitment in vivo:
evidence for stimulus specificity and a critical role in collagen IV
remodeling. J Leukoc Biol 2008, 83:864–874.
48. Elmetwali T, Searle PF, McNeish I, Young LS, Palmer DH: CD40 ligand
induced cytotoxicity in carcinoma cells is enhanced by inhibition of
metalloproteinase cleavage and delivery via a conditionally-replicating
adenovirus. Mol Cancer 2010, 9:52.
49. Geurts N, Opdenakker G, Van den Steen PE: Matrix metalloproteinases as
therapeutic targets in protozoan parasitic infections. Pharmacol Ther
2012, 133:257–279.
doi:10.1186/1471-2334-13-331
Cite this article as: de Oliveira et al.: High levels of soluble CD40 ligand
and matrix metalloproteinase-9 in serum are associated with favorable
clinical evolution in human visceral leishmaniasis. BMC Infectious Diseases
2013 13:331.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
